Elsevier

Clinical Therapeutics

Volume 39, Issue 8, August 2017, Pages 1581-1598
Clinical Therapeutics

Original Research
A Comprehensive Review of Immunization Practices in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients

https://doi.org/10.1016/j.clinthera.2017.07.005Get rights and content

Abstract

Background

Vaccine-preventable diseases, especially influenza, varicella, herpes zoster, and invasive pneumococcal infections, continue to lead to significant morbidity and mortality in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.

Methods

We highlight guideline recommendations for the use of key vaccines in SOT and HSCT recipients and to review the latest evidence and developments in the field.

Results

Physicians should vaccinate individuals with end-stage organ disease, as vaccine seroresponse rates are higher pretransplantation. Most live attenuated vaccines continue to be contraindicated post-transplantation, but there are emerging safety profile and efficacy data to support the use of specific live attenuated vaccines, such as measles, mumps, and rubella in pediatric liver or kidney transplant recipients who are on low-level maintenance immunosuppression and without recent history of allograft rejection. An inactivated subunit varicella zoster virus vaccine is currently awaiting US Food and Drug Administration approval. While we await the safety profile and efficacy data of this subunit vaccine in transplant recipients, it will likely benefit immunocompromised individuals, including transplant recipients, because the live attenuated herpes zoster vaccine is currently contraindicated in transplant recipients and transplantation candidates receiving immunosuppression.

Conclusions

There is currently no evidence that vaccines lead to allograft rejection in SOT recipients. Household contacts of SOT and HSCT recipients should be vaccinated per the Advisory Committee on Immunization Practices schedule and recommendations.

Implications

Immunizations remain underutilized in transplantation patients. Although efficacy of vaccines in SOT and HSCT may be suboptimal, partial protection is preferred over no protection.

Section snippets

General Principles of Immunizations in Transplant Recipients

Vaccine-preventable diseases, such as influenza and pneumococcal disease, still cause considerable morbidity and mortality in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients. Although national and international guidelines advocate a systematic approach to pre- and post-transplantation immunizations in SOT and post-transplantation re-immunizations in HSCT recipients,1, 2, 3, 4, 5 wide variations in immunization practices6 and deviations from guidelines

Immunizations in Solid Organ Transplantation Candidates

Solid organ transplantation candidates are more likely to develop vaccine-induced immunity compared with SOT recipients receiving immunosuppressive agents. Physicians who provide care to potential transplantation candidates should vaccinate them in accordance with published guidelines as early as possible in the course of their end-stage organ disease.1, 2, 5 The pretransplantation evaluation is a convenient time to review immunization records and initiate these immunizations,1, 2, 5 guided by

Immunizations in Solid Organ Transplant Recipients

Immunizations after transplantation may be variably immunogenic but are still important in providing a measure of protection against vaccine-preventable diseases. There is emerging literature on the use of post-transplantation hepatitis B vaccine, with or without adjuvants, to shorten the duration of hepatitis B immunoglobulin after liver transplantation for hepatitis B, but this issue is outside the scope of the present review. This review will summarize the most common immunizations given

Lack of Association between Immunizations and Allograft Rejection

Influenza immunizations had been withheld in the past due to the fear of triggering allograft rejection, based on case reports and small case series. However, larger studies have failed to support any clinically relevant association between immunizations and rejection or allograft dysfunction.12, 37, 38 The evidence from these studies is summarized and only a few examples will be cited herein. A large multicenter study of more than 5000 patients in 28 heart transplantation programs that had a

Immunizations in Hematopoietic Stem Cell Transplant Recipients

In HSCT recipients, post-transplantation immune recovery begins with engraftment of neutrophils, but lymphocyte recovery is a prolonged process. Reconstitution of the immune system requires at least several months post-transplantation, and some patients continue to have immune deficits for several years after HSCT. Thus, much of previous donor and recipient immunity to specific pathogens is lost, and HSCT programs generally carry out a comprehensive post-transplantation revaccination program.

Background

Live attenuated vaccines (Table IV) are generally contraindicated in SOT and HSCT recipients due to the theoretical risk of vaccine-acquired infections. However, transplant recipients are at increased risk for developing severe or disseminated forms of infectious diseases from wild-type pathogens and, given that there are growing safety profile and effectiveness data for select live attenuated vaccines in transplant recipients, we will review new developments for each live attenuated vaccine

Immunizations for Transplant Recipients Planning Travel

When transplant recipients are planning international travel, both clinicians and patients should be familiar with the American Society of Transplantation Infectious Diseases Guidelines for travel70 and other similar guidelines. For international travel, especially to countries or areas with suboptimal sanitation, it is preferable to wait until 1 year after transplantation, although for some patients it may be advisable to wait longer (eg, if they are experiencing organ rejection or infections

Immunizations for Household Contacts of Transplant Recipients

Household contacts of transplant recipients should receive immunizations, whether live attenuated or inactivated, as indicated for the general public (Table IV). Avoidance of recently immunized household contacts by transplant recipients is not evidence-based and is unnecessary. The IDSA Guidelines also state that the live travel-related vaccines (YF, oral typhoid) may be administered to household contacts.2 Among vaccines administered to the general public, the only vaccine for which household

Conclusions

Immunizations remain underutilized in transplantation candidates, transplant recipients, and household contacts. Vaccine-preventable diseases, particularly influenza, varicella, HZ, and invasive pneumococcal infections, continue to cause considerable morbidity and mortality in SOT and HSCT recipients. More systematized protocols and more vigorous endorsements of immunization programs are needed. Non-live vaccines are tolerable for transplantation candidates and transplant recipients.

Conflicts of Interest

P.P.C and R.K.A have no conflicts of interest to disclose.

Acknowledgment

P.P.C and R.K.A contributed to drafting the manuscript. Both authors critically revised and approved of the final version of the manuscript to be published.

References (70)

  • D. Kumar et al.

    Influenza vaccination in the organ transplant recipient: review and summary recommendations

    Am J Transplant

    (2011)
  • C. White-Williams et al.

    Improving clinical practice: should we give influenza vaccinations to heart transplant patients?

    J Heart Lung Transplant

    (2006)
  • K.M. Posfay-Barbe et al.

    Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic

    Am J Transplant

    (2012)
  • A. Weinberg et al.

    Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients

    Am J Transplant

    (2006)
  • J. Levitsky et al.

    Varicella infection following varicella vaccination in a liver transplant recipient

    Am J Transplant

    (2002)
  • M.H. Mazur et al.

    Herpes zoster at the NIH: a 20 year experience

    Am J Med

    (1978)
  • M. Boeckh et al.

    Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study

    Blood

    (2006)
  • N.C. Issa et al.

    Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients

    Biol Blood Marrow Transplant

    (2014)
  • M. Shinjoh et al.

    Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation

    Vaccine

    (2008)
  • Y. Kawano et al.

    Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients

    Vaccine

    (2015)
  • B. Wyplosz et al.

    Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation

    Am J Transplant

    (2013)
  • K. Hayakawa et al.

    Persistent seropositivity for yellow fever in a previously vaccinated autologous hematopoietic stem cell transplantation recipient

    Int J Infect Dis

    (2015)
  • N. Bakare et al.

    Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS)

    Vaccine

    (2010)
  • C.N. Kotton et al.

    Travel medicine and transplant tourism in solid organ transplantation

    Am J Transplant

    (2013)
  • L.G. Rubin et al.

    2013 IDSA clinical practice guideline for vaccination of the immunocompromised host

    Clin Infect Dis

    (2014)
  • C.A. Dykewicz

    Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

    Clin Infect Dis

    (2001)
  • Kidney Disease Improving Global Outcomes (KDIGO) Guidelines....
  • M.P. Hudspeth et al.

    Post-hematopoietic stem cell transplant immunization practices in the Pediatric Blood and Marrow Transplant Consortium

    Pediatr Blood Cancer

    (2010)
  • E.J. Ariza-Heredia et al.

    Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice

    Transpl Infect Dis

    (2014)
  • D. Roll et al.

    Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

    Infection

    (2012)
  • C. Cohet et al.

    Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series

    BMJ Open

    (2016)
  • P. Perez-Romero et al.

    Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe

    Clin Microbiol Infect

    (2015)
  • F.P. Hurst et al.

    Outcomes associated with influenza vaccination in the first year after kidney transplantation

    Clin J Am Soc Nephrol

    (2011)
  • P. Vermeiren et al.

    Influenza vaccination and humoral alloimmunity in solid organ transplant recipients

    Transpl Int

    (2014)
  • M.J. Salles et al.

    Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs

    Clin Transplant

    (2010)
  • Cited by (87)

    • Coronavirus Disease-2019 and Implications on the Liver

      2023, Clinics in Liver Disease
      Citation Excerpt :

      Data on COVID-19 immunization in LT recipients have shown the vaccines to be safe and effective at preventing hospitalization and death.63 Available data do not show an increased risk of alloimmunity and graft rejection.70 It is important to note that none of the available vaccines contain live SARS-CoV-2; therefore, replication of SARS-CoV-2 after vaccination is not possible even in immunocompromised patients.

    View all citing articles on Scopus
    View full text